Nuvilex's Major Achievements Set Stage for Big 2014
(firmenpresse) - BALTIMORE, MD -- (Marketwired) -- 08/06/13 -- In a newly released research update, Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes in a research update that Nuvilex Inc.'s (OTCQB: NVLX) just released shareholder update indicates that recent and pending milestones set the stage for a big 2014 for the Company. Nuvilex Inc. is an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of medical marijuana for use in oncology treatment.
Nuvilex owns exclusive worldwide rights to the live-cell encapsulation-based platform technology for any and all cancer types, including a pancreatic cancer treatment that successfully completed Phase II clinical trials. This platform, which essentially serves as an existing therapy booster, is based upon its live-cell encapsulation technology and delivery system and enhances the quality of life.
In the Goldman Opportunity Research update on the Company, analyst Rob Goldman outlines his investment thesis.
"On the heels of the recent cancer treatment transaction, management noted that Nuvilex intends to acquire the worldwide exclusive rights to the use of the live-cell encapsulation technology for the development of treatments for diabetes from SG Austria with the closing of the transaction expected at the end of October 2013. Estimated annual diabetes drug sales in the U.S. are $22 billion, thus providing huge market potential for the Company. Funds for this acquisition have already been committed and the final paperwork is executed."
"Given the correlation between individuals with diabetes and their 8-fold increased risk for pancreatic cancer, it is a natural fit into at least one of the Company's overall clinical directions. Management plans to begin preparing for future in-depth studies in the fourth quarter of this year. Considering that the diabetes treatment data indicates that it could eliminate the need for insulin therapy, Nuvilex is moving toward introducing a game-changing treatment platform that is potentially worth billions in annual sales. Moreover, Nuvilex has now transformed itself into a major player in two of the largest and most lucrative health care treatment categories, oncology and diabetes."
To view Nuvilex reports and articles or to download the report in its entirety, please visit .
Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. For more information, visit .
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit .
(OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.08.2013 - 07:02 Uhr
Sprache: Deutsch
News-ID 1252046
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BALTIMORE, MD
Phone:
Kategorie:
Venture Capital
Anmerkungen:
Diese Pressemitteilung wurde bisher 116 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nuvilex's Major Achievements Set Stage for Big 2014
"
steht unter der journalistisch-redaktionellen Verantwortung von
Goldman Small Cap Research, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
